Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPrevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status
Bulletin du Cancer, 10/19/09
Bensouda Y et al. – CA15–3, a peptide derived from MUC–1, an hormonally–regulated protein, is the most widely used serum marker of breast cancer. CA15–3 level increases at the metastatic phase in 50–80% breast cancer patients. The data confirm that CA 15–3 is very variably elevated at time of metastatic relapse of breast cancer, and this is dependant on HR status.
Related Articles
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Relevance Score: 74%
Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09
Relevance Score: 72%
Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09
Relevance Score: 72%
Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09
Relevance Score: 72%
Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09
Relevance Score: 72%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Bevacizumab and breast cancer: current therapeutic progress and future perspectives
Expert Review of Anticancer Therapy, 12/04/09
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
Cancer Treatment Reviews, 12/04/09
Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer
Cancer Treatment Reviews, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor